Kuros BiosciencesCSBTF 71 Days Payable is 160.21 as of Dec. 2025, which is 28% above its 10-year median of 124.76. GuruFocus rates CSBTF with a GF Score™ of 71/100 and a GF Value™ of $54.72 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Kuros Biosciences ranks better than 84.65% on this metric.
The historical rank and industry rank for Kuros Biosciences's Days Payable or its related term are showing as below:
CSBTF'
s Days Payable Range Over the Past 10 Years
Min: 49.34 Med: 124.76 Max: 234.37
Current: 196.58
During the past 13 years, Kuros Biosciences's highest Days Payable was 234.37. The lowest was 49.34. And the median was 124.76.
CSBTF's Days Payable is ranked better than 84.65% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs CSBTF: 196.58
Kuros Biosciences's Days Payable
increased
from Dec. 2024 (80.84) to Dec. 2025 (160.21).
It may suggest that Kuros Biosciencesdelayed paying its suppliers.
Kuros Biosciences Days Payable Related Terms
Kuros Biosciences Days Payable Historical Data
* Premium members only.
The historical data trend for Kuros Biosciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Kuros Biosciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Kuros Biosciences's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kuros Biosciences (CSBTF) has a Days Payable of 160.21 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Kuros Biosciences and its competitors. This is 28% above median its historical median of 124.76. Over the past decade, Kuros Biosciences' Days Payable has ranged from 49.34 to 234.37. According to the industry distribution chart, Kuros Biosciences ranks #122 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 15.3%.
Is Kuros Biosciences' Days Payable too high?
Kuros Biosciences' current Days Payable of 160.21 is 28% above median its 10-year median of 124.76. Over the past 10 years, this metric has ranged from a low of 49.34 to a high of 234.37. The Medical Devices & Instruments industry median Days Payable is 67.87. Kuros Biosciences' value of 160.21 is 136.1% above this industry median. Based on the distribution chart, Kuros Biosciences ranks #122 out of 795 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Kuros Biosciences has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Kuros Biosciences ranks #122 out of 795 companies for Days Payable. This places Kuros Biosciences in the top 15% of its industry — outperforming the majority of peers. The industry median Days Payable is 67.87. Kuros Biosciences' value of 160.21 is 136.1% above this benchmark. Historically, Kuros Biosciences' own Days Payable has ranged from 49.34 to 234.37 over the past decade. While the company's 10-year median is 124.76 vs. the industry median of 67.87, Kuros Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kuros Biosciences's current Days Payable of 160.21 is 136.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Kuros Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuros Biosciences's current Days Payable is 160.21, which is 28% above median its own 10-year median of 124.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $54.72, compared to a current price of $22.72 — trading 58.5% below its estimated fair value. The current Days Payable is 160.21, which is 28% above median its 10-year median of 124.76 and 136.1% above the Medical Devices & Instruments industry median of 67.87. Kuros Biosciences' overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current Days Payable is 160.21 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuros Biosciences (CSBTF) Overvalued in 2026?
Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued.
The current stock price of $22.72 is trading 58.5% below its estimated GF Value™ of $54.72.
GuruFocus considers Kuros Biosciences to be Significantly Undervalued.
Key valuation signals for CSBTF:
Days Payable: 160.21 (28% above median its 10-year median of 124.76)
GF Value™: $54.72 vs. price of $22.72 (58.5% below fair value)
Industry Position: 136.1% above the Medical Devices & Instruments median (#122 of 795)
No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
71GF Score
Get the complete analysis for CSBTF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBTF has been successfully added to your 
